Our hematologic oncologists at Willamette Valley Cancer and Research Center are on the forefront of important work that is changing the treatment landscape for blood cancers. Read more.
Cancer can be frightening. There's no denying it. So I can understand why, in a situation that feels out of control, patients seek ways to take control back. One of the most common ways is through self-treatment. Read more.
Clinical trial research at Willamette Valley Cancer Institute and Research Center (WVCI) was published January in the New England Journal of Medicine (NEJM), marking the second time in six months cancer research at WVCI appeared in the presitigous journal. Read more.
In July 2013, the Medicare Patient Access to Cancer Treatment Act (H.R. 2869), a bipartisan bill, was introduced to remedy a flawed Medicare payment policy that pays more to hospitals than cancer care centers for the same care. This legislation would equalize reimbursements for cancer treatments regardless of whether a service is delivered in the hospital or a physician office. We encourage you to reach out to your Representatives and encourage them to cosponsor the Medicare Patient Access to Cancer Treatment Act. Read more.
Dr. Jeff Sharman, a hematologist oncologist at Willamette Valley Cancer Institute and Research Center, was published in the New England Journal of Medicine last week for clinical trials held at WVCI on a breakthrough drug for chronic lymphocytic leukemia (CLL). Read more.